Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.142.201.19
dgid:
enl:
npi:0
Growth Hormone Deficiency

Undiagnosed GHD common in irradiated survivors of childhood brain tumors

Posted on

The prevalence of undiagnosed growth hormone deficiency (GHD) amongst survivors of childhood brain tumors who were treated with irradiation with no growth hormone (GH) test at final height is high, according to a study.

-Advertisement-
-Advertisement-

In this cross-sectional study, the medical charts of patients with childhood brain tumors who had survived 5 years were evaluated. Participants had a median age of 21.7 years (range 15.1 – 33.8 years) at follow-up and 14.8 years (range 5.1 – 23.4 years) since diagnosis. Participants without a GH test at the final height were offered a GH stimulation test.

Of the 41 patients included in the study, 11 had been treated with proton irradiation and 30 with photon irradiation. Of the 21 survivors who had undergone GH testing, 18 were found to have GHD. Of the 20 participants who did not have a GH test at final height, 16 opted to be tested, with 8 patients diagnosed with GHD.

Overall, 63% of participants in the study had GHD.

Reference
Baunsgaard MM, Helligsoe ASL, Henriksen LT, et al. Growth hormone deficiency in adult survivors of childhood brain tumors treated with radiation. Endocr Connect. 2022;EC-22-0365. doi: 10.1530/EC-22-0365. Epub ahead of print. PMID: 36507776.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-